Results 131 to 140 of about 255,745 (263)

Fluorescence imaging for assessing tissue perfusion after revascularization in peripheral arterial disease. [PDF]

Sci Rep
Kluckner M, von Kroge PH, Duprée A, Wippel D, Schönherr L, Gruber L, Enzmann FK, Wipper S.   +7 more
europepmc   +1 more source

Integrated Clinical and Proteomic Profiling of CD19 Chimeric Antigen Receptor T Cell Therapy in Progressive Systemic Sclerosis

Arthritis &Rheumatology, EarlyView.
Objective To characterize the clinical, immunologic, and proteomic changes associated with CD19 chimeric antigen receptor T cell therapy in patients with progressive systemic sclerosis (SSc). Methods Patients with progressive SSc received CD19 chimeric antigen receptor (CAR)‐T cell therapy and were observed longitudinally for safety, clinical efficacy,
Chenhan Jia, Wanyi Lin, Zhangyi Zhao, Fenglin Wu, Chaoyu Gu, Yuankai Sun, Zhe Ding, Chang Wei, Xinyu Li, Cuiwei Xie, Peng Xia, Zhen Xia, Xuesong Liu, Shaoying Yang, Chunyan Zhang, Hanlin Yin, Liangjing Lu   +16 more
wiley   +1 more source

Histological concordance of medial arterial calcification between tibial and peroneal arteries in advanced peripheral arterial disease. [PDF]

JVS Vasc Sci
Adler S, RuizdelRio J, Eliceiri B, Gaffey AC.   +3 more
europepmc   +1 more source

Comparative transcriptional profiling of key macrophage and fibroblast subpopulations in rheumatoid arthritis‐associated lung disease

Arthritis &Rheumatology, Accepted Article.
Objective Rheumatoid arthritis (RA) often involves extra‐articular complications, including interstitial lung disease (ILD) and/or pulmonary nodules. Transcriptomic profiling of lung tissue provides the opportunity to directly assess cell‐specific gene expression and corresponding pathway activation in different types of rheumatoid lung disease ...
Tracy Tabib, Ogechukwu Ezenwa, Joshua Sciurba, Eleanor B. Valenzi, John Sembrat, Brittany Cody, Jishnu Das, Robert Lafyatis, Dana P. Ascherman   +8 more
wiley   +1 more source

Impact of peripheral arterial disease and cerebrovascular disease on outcomes in patients undergoing PCI. [PDF]

Int J Cardiol Heart Vasc
Gadhe P, Sharma R, Farhan S, Song D, Kapur V, Tarricone A, Sartori S, Oliva A, Feng Y, Krishnan P, Kini A, Mehran R, Sharma S.   +12 more
europepmc   +1 more source

Cost–benefit analysis of screening programme for diabetic retinopathy in Bulgaria

British Journal of Clinical Pharmacology, EarlyView.
Aims Late‐diagnosed diabetic retinopathy (DR) is difficult and expensive to treat. Screening programmes can identify the disease early and reduce the costs of its future treatment. This study aims to analyse the cost–benefit of screening programmes for DR.
Iva Nenkova, Yoana Lilova, Alexander Oscar, Alina Levi, Maria Kamusheva, Guenka Petrova   +5 more
wiley   +1 more source

A Sedentary Behaviour Reduction Programme in Patients With Peripheral Arterial Disease: A Mixed-Method Feasibility Study. [PDF]

Int J Vasc Med
Said M, Tawfick W, Edwardson CL, Carvalho M, Sultan S, Alawy M, Filandrianou E, Nolan M, Jones J.   +8 more
europepmc   +1 more source

Pentoxifylline dose finding trial in preterm neonates with suspected late onset sepsis (PTX‐trial)

British Journal of Clinical Pharmacology, EarlyView.
Aim The aim of this study (PTX‐trial) is to determine the optimal dose of pentoxifylline (PTX) in preterm neonates (gestational age < 30 weeks) with (suspected) late onset sepsis (LONS). Methods The PTX‐trial is a prospective multicentre open‐label sequential dose‐optimization study with an adapted continual reassessment method.
Serife Kurul, H. Rob Taal, Jan Mazela, Ryszard Lauterbach, Irwin K. M. Reiss, Karel Allegaert, Robert B. Flint, Sinno H. P. Simons   +7 more
wiley   +1 more source

The role of albumin-globulin ratio in peripheral arterial disease among hypertensive adults: evidence from a large-scale multicenter study. [PDF]

Front Endocrinol (Lausanne)
Yu C, Yang Y, Liao X, Wu L.
europepmc   +1 more source

Blood pressure effects of SGLT2 inhibitors and GLP‐1 receptor agonists: Mechanisms, trial evidence and Real‐world data

British Journal of Clinical Pharmacology, EarlyView.
SGLT2 inhibitors and GLP‐1 receptor agonists modestly lower blood pressure across diverse patient populations, including those without diabetes. These effects appear largely independent of glycaemic control and offer additive value in high‐risk patients with overlapping comorbidities.
Andrej Belančić, Yusuf Ziya Sener, Marijana Vučković, Joseph Edgar Blais, Almir Fajkić, Emina Sher, Mislav Radić, Josipa Radić   +7 more
wiley   +1 more source